Molecular Templates, Inc.
(NASDAQ : MTEM)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Interested in Gold Updates?
Receive the latest updates on the gold and silver markets.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
AMGNAmgen Inc.
0.41%183.731.1%$863.66m
GILDGilead Sciences, Inc.
-0.43%80.590.9%$826.67m
CELGCelgene Corporation
0.98%94.771.2%$768.34m
JUNOJuno Therapeutics, Inc.
1.96%86.6513.5%$580.24m
BIIBBiogen Inc.
0.16%287.921.2%$510.77m
REGNRegeneron Pharmaceuticals, Inc.
-1.18%319.222.7%$396.00m
VRTXVertex Pharmaceuticals Incorporated
-1.53%158.531.9%$353.89m
ALXNAlexion Pharmaceuticals, Inc.
-0.51%118.252.0%$255.32m
NKTRNektar Therapeutics
1.86%85.006.0%$251.64m
ILMNIllumina, Inc.
0.32%227.293.5%$231.45m
BLUEBluebird Bio, Inc.
2.26%210.1016.1%$196.30m
AAgilent Technologies, Inc.
1.53%72.171.5%$178.30m
INCYIncyte Corporation
0.26%85.742.5%$154.53m
BMRNBioMarin Pharmaceutical Inc.
1.06%84.744.4%$122.46m
EXASExact Sciences Corporation
-0.21%47.9126.0%$117.92m

Company Profile

Threshold Pharmaceuticals, Inc. engages in the development of therapeutics for treating tumors. It offers the Evofosfamide which designed as a prodrug that is activated under the extreme hypoxic conditions commonly found in tumors, but not typically in healthy tissues, and TH-3424 which is a small-molecule drug candidate for the treatment of liver, castrate resistant prostate cancer, T-cell acute lymphoblastic leukemias, and other cancers. The company was founded by Jeffrey W. Bird on October 17, 2001 and is headquartered in South San Francisco, CA